Subcutaneous Xenograft Model

Human cancer cell line xenografts establish tumors when placed in immunodeficient Nude athymic mice. The efficacy of novel compounds in inhibiting their growth and development as well as the mechanisms involved can be investigated in this model. Below is a list of available routinely used tumor cell lines at MuriGenics:

  • Prostate: LNCAP, PC3
  • Breast: MCF7
  • Colorectal: HT29, SNU, C2B, HCT-116, COLOHSR
  • Lung: A549
  • Melanoma: WM-266-4
  • Pancreatic: PANC-1
  • Glioblastoma: U87-MG, LN229
  • Neuroblastoma: SK-N-MC
  • Acute Myeloid Leukemia: K562
  • Multiple Myeloma: MMI.S


Preclinical Drug Efficacy Studies


Mice (Athymic Nude mice – Balb/c background Foxn1nu mutation)

Basic Methodology

Immunodeficient mice (Nude mice) are subcutaneously injected with a human tumor cell line. Mice are dosed p.o., i.v. or i.p. with a compound(s) of interest. Inhibition of tumor growth after treatment is determined through tumor microcaliper measurement.


Clinical observations, body weight, tumor measurements (microcaliper), blood chemistries, histopathology, cytokine profiling using ELISA and Luminex multiplex assays

Literature References:

Riondel J, Jacrot M, Picot F, Beriel H, Mouriquand C, Potier P. (1986) Therapeutic response to taxol of six human tumors xenografted into nude mice. Cancer Chemotherapy and Pharmacology; 17(2): 137-142.

Wu WD, Fang CH, Yang ZX. (2008) Effects of RNA interference on epidermal growth factor receptor expression in breast cancer cells: a study in tumor-bearing nude mice. Journal of Southern Medical University; 28(1): 60-4.